A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).

开始日期2019-09-23

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT03674502 / Terminated临床1期

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma

This study is a first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, PK, and PD of ADU-1604 and explore initial clinical activity in adults with metastatic melanoma.

开始日期2018-11-08

申办/合作机构

Aduro BioTech, Inc.

NCT03190265 / Completed临床2期IIT

A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with administration of CRS-207 alone (Arm B) in patients with pancreatic cancer.

开始日期2017-12-14

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+3]

100 项与 Aduro BioTech, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Aduro BioTech, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Aduro BioTech, Inc. 相关的文献（医药）

2024-03-01·Nature chemical biology

Activation of human STING by a molecular glue-like compound

Article

作者: Cho, Charles Y ; McWhirter, Sarah M ; Ross, Nathan T ; Bai, Xiao-Chen ; Patel, Sejal J ; Tallarico, John A ; Digan, Mary Ellen ; Henault, Martin ; Yu, Gary ; Tutter, Antonin ; Canham, Stephen M ; Wang, Yuan ; Feng, Yan ; Zheng, Lianxing ; Sivick, Kelsey E ; Mao, Xiaohong ; Michaud, Gregory A ; Li, Jie ; Brittain, Scott M ; Chen, Christine H ; Liu, Guoxun ; Pham, Helen T ; Nicholson, Thomas B ; Wu, Hua ; Zhang, Xuewu ; McKenna, Jeffery M ; Jenkins, Jeremy L ; Tria, George S ; Chen, Yu ; Hornak, Viktor ; Chen, Lihao ; Jain, Rishi K ; Schirle, Markus ; Broom, Wendy ; Miller, Howard R

Abstract:

Stimulator of interferon genes (STING) is a dimeric transmembrane adapter protein that plays a key role in the human innate immune response to infection and has been therapeutically exploited for its antitumor activity. The activation of STING requires its high-order oligomerization, which could be induced by binding of the endogenous ligand, cGAMP, to the cytosolic ligand-binding domain. Here we report the discovery through functional screens of a class of compounds, named NVS-STGs, that activate human STING. Our cryo-EM structures show that NVS-STG2 induces the high-order oligomerization of human STING by binding to a pocket between the transmembrane domains of the neighboring STING dimers, effectively acting as a molecular glue. Our functional assays showed that NVS-STG2 could elicit potent STING-mediated immune responses in cells and antitumor activities in animal models.

2023-01-04·Clinical cancer research : an official journal of the American Association for Cancer Research

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Article

作者: Lewis, Nancy ; Nair, Nitya ; Kasper, Stefan ; Steeghs, Neeltje ; Sweis, Randy F. ; Müller, Thomas ; Pelletier, Marc ; Kattenhorn, Lisa ; Bean, Andrew ; Meric-Bernstam, Funda ; Chen, Xinhui ; Shimizu, Toshio ; Stradella, Agostina ; Sandhu, Shahneen ; Bhatia, Shailender ; Luke, Jason J. ; Long, Georgina V. ; Dummer, Reinhard ; McWhirter, Sarah M. ; Hamid, Omid ; Spreafico, Anna

Abstract:

Purpose::

The stimulator of IFN genes (STING) is a transmembrane protein that plays a role in the immune response to tumors. Single-agent STING agonist MIW815 (ADU-S100) has demonstrated immune activation but limited antitumor activity. This phase Ib, multicenter, dose-escalation study assessed the safety and tolerability of MIW815 plus spartalizumab (PDR001), a humanized IgG4 antibody against PD-1, in 106 patients with advanced solid tumors or lymphomas.

Patients and Methods::

Patients were treated with weekly intratumoral injections of MIW815 (50–3,200 μg) on a 3-weeks-on/1-week-off schedule or once every 4 weeks, plus a fixed dose of spartalizumab (400 mg) intravenously every 4 weeks.

Results::

Common adverse events were pyrexia (n = 23; 22%), injection site pain (n = 21; 20%), and diarrhea (n = 12; 11%). Overall response rate was 10.4%. The MTD was not reached. Pharmacodynamic biomarker analysis demonstrated on-target activity.

Conclusions::

The combination of MIW815 and spartalizumab was well tolerated in patients with advanced/metastatic cancers, including in patients with anti-PD-1 refractory disease. Minimal antitumor responses were seen.

2022-05-31·Proceedings of the National Academy of Sciences of the United States of America1区 · 综合性期刊

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I–deficient and MHC I ⁺ tumors

1区 · 综合性期刊

Article

作者: Snyder, Gail ; Nicolai, Christopher J. ; Picton, Lora K. ; Zhang, Li ; Wolf, Natalie K. ; Ndubaku, Chudi O. ; Raulet, David H. ; Blaj, Cristina ; McWhirter, Sarah M. ; Garcia, K. Christopher

Significance:

Immunotherapy provides long-term remissions in numerous types of cancer but is ineffective in most tumors with poor immune cell infiltrates or lacking T cell epitopes or MHC I molecules. Agents that activate the STING protein showed promise in several MHC I + and MHC-deficient tumor models in mice, where they induced powerful antitumor CD8 + T cell and natural killer (NK) cell responses, respectively. They were less effective in numerous other tumor models and yielded mixed results in the clinic in human patients. This report demonstrates strong synergy between a STING agonist and an IL-2 superkine in effectively curing difficult-to-treat MHC-deficient and MHC-positive tumor models in mice by mobilizing T cells and NK cells. This combination therapy shows considerable promise for clinical application.

项与 Aduro BioTech, Inc. 相关的新闻（医药）

2024-09-05

·艾美达医药咨询

医药科创板破零，大家却沉默了

近日，A股科创板终于迎来一家生物医药IPO，这距离上一家医药企业科创板上市已经近一年之久。 CRO益诺思，在新规的背景下且恰逢医药外包行业处于低谷期之时，尽管2024年利润端同比下降幅度较大的情况下，依旧顺利实现上市。益诺思身上具备了“几近完美”的IPO条件：1）公司大股东是上海医工总院，由国药集团100%控股，可以算是央企；2）发行规模小（募资总额约6.72亿）且符合跟投新规（海通证券跟投5%发行股份，金额约3358.8万）；3）盈利趋势好（首先是盈利，其次近三年利润增长态势好）且市盈率低（15.4倍），客户群优质；4）核心管理层整体素质高，学术科研、药政背景深厚，亦是高加分项。而这一次的“破冰”，似乎并没有给市场带来更多的良好预期，反而可能让大家的“寒气”更加重了。恰恰是如此完美的IPO天团，这让有科创板上市计划或者准备IPO的生物医药企业们带来更多信心上的打击，另外也可能引发了更多的思考：勇敢拥抱国资？寻求其他的融资出路？聚焦专注商业化？.. 到了如今这个地步，大家应该不羞于谈论国内Biotech公司的破产或者清算，它就像自然界的生存代谢一样稀松平常，而那些千方百计要寻求生路的Biotech，在值得钦佩的同时也应使出浑身解数，接受时代洪流的洗礼，做出不一样战略选择。在这一点上，我们不妨以海外为鉴。 01 关于商业化趋势在讲求市占率、现金流的创新药后时代，商业化逐渐成为一个高度分工的区块。从已经完成的国内Biotech进化史来看，能够通过自家产品实现一定规模商业化团队和能力构建的公司仍在少数，如百济神州、信达生物、艾力斯、康方生物等。抛开出海不谈，上述在国内搭建商业化平台且上岸的药企都有相似的共性，都逃离不出“大单品”、“融资能力强”、“立项能力强或者差异化布局”等特性，直接导向产品放量、竞争格局好、充足现金储备等因素；现在，大多数走到商业化的Biotech则均困顿于“有产品，但现金流无法支撑其大规模扩建走到盈利甚至盈亏平衡那一步”。于是，我们看到国内产品权益更迭交易近年正在密集发生。放眼海外，已上市的Biotech如果有潜力产品在临近商业化阶段同时现金管道无法支撑商业化开支的背景下，除了“卖”，还有通过出让产品收益进行融资、向专门的生物医药金融机构申请债权融资的常见案例。比较典型的案例莫过于Verona Pharma，其在2024年5月与Oaktree Capital和OMERS Life Sciences达成了一项6.5亿美元战略融资，融资具体结构为“债务融资+收入权益购买和销售协议（RIPSA方式）”。其中，定期贷款部分“5500万美元（交易达成后可提）+7000万美元（Ensifentrine遭FDA批准后可提） +1.75亿美元（达到某些净销售里程碑后分两批提取）+1亿美元（支持策略灵活性）”；RIPSA方式，Verona在Ensifentrine批准后1亿美元、Ensifentrine达到某些净销售额里程碑后有资格额外提取1.5亿美元，而投资人在RIPSA期限内可获得Ensifentrine全球销售的5-6.5%分成；同时在RIPSA方式协定中，Verona最终支付给资金方总收入利息融资上限为实际融资金额的1.75倍，Verona可在融资后的前三年内以较低的倍数赎回RIPSA。这类交易建立在公司对产品未来的有非常充足信心和把握上，通过出让产品的销售分成获得中短期的流动性，如果商业化顺利公司可以通过产品的放量以较低的金额赎身；投资人层面，相当于看好“Ensifentrine”的未来，在通过债权融资锁定固定的利息收入，同时可通过享受优质药物产品的商业化红利拔高债权收益上限。当然，如果新药产品的商业化不顺利，可能将遭遇资金方的鲸吞反噬，最终将产品权益甚至公司全数交出（Oaktree Capital是著名的困境投资者，如在足球领域收购过国际米兰俱乐部）。海外，这类债权融资并不在少数，如近期刚获得FDA批准的TCR-T疗法（afami-cel）研发商Adaptimmune就与Hercules Capital达成了1.25亿美元的债务融资；而国内选择进行债务融资的Biotech并不是非常多，一个是缺少基于生物医药产品融资或者债权融资的专业机构，另一个原因则是一般Biotech股东结构分散和风险偏好很难达成这样的一锤子交易。所以，目前国内手握商业化产品的Biotech选择与国内大药企合作商业化的不在少数，归根结底在于短期牺牲变大的可能性降低风险来换取更稳定的收入结构，不少公司都取得了不错的阶段性成果。比如亚盛医药的奥雷巴替尼国内与信达生物共同商业化，基石药业则是分别将阿伐替尼、普拉替尼国内商业化交给恒瑞医药、艾力斯，加科思则是将KRAS G12C和SHP-2国内权益交给艾力斯等；其中，亚盛医药、基石药业都在2024H1实现事件性盈利，加科思则是通过这类交易解决了一些问题。从当下融资渠道收窄的趋势下看，Biotech们将日趋积极寻求国内的商业化合作，长期看国内大药企或者有商业化能力的Biopharma将在未来有望以较优惠的价格收拢优质产品，实现强者恒强。 02 IPO&再融资受限，Newco引领出海热潮生物医药IPO和二级再融资市场的规模显著受限。在A股IPO审核短期无望打开的背景下，港股成为Biotech的唯一或唯二选择，以最近上市表现出色的同源康医药为例，IPO募资净额大约5.06亿港元，在公司现金流较为紧张和近两年公司亏损额在3亿左右的背景下，IPO募资金额只能提供1.5年现金管道（这样小型的募资特色也是现有低迷流动性驱使下的结果）；另外，港股Biotech再融资通道也被关上，主要原因是长期的市场低迷，市场的承接力始终十分有限。美股IPO同样是一条出路，但只有极少数顶级的Biotech才能在美国获得市场化的发行，但付出的时间、资源成本都不是一般公司能够接受的。由此，有限的获取现金管道方式，使得国内Biotech只剩下出海的这一条出路，而Newco模式引领风潮，由非常多原因构成，一方面Biotech们“时间紧、任务重”，如果坚持选择与MNC合作可能会付出较长的谈判成本还要忍受较大告吹风险；另一方面，Newco方式带来的灵活性，较传统的License out合作方式使得授权方有更多的想象空间；更重要的是，它给予了大量非头部Biotech全新出海的机会。目前，Newco模式最具弹性的部分莫过于国内Biotech在将自家管线授予出去后同时获得对手方的股权，这部分股权相当于期权，随着该项目海外临床的发展而收获资产增值。从过往案例来看，国内无论是海思科还是恒瑞医药，在各自的TYK2项目（Alumis）和TSLP项目（Aiolos）上都缺乏一定“远见”，但反面直接应证了Newco模式的潜力。在Newco这类交易结构中，除了交易产品自身的潜力以外，运作海外壳公司的操盘方对项目的成长具备决定性导向，这可能成为投资者研判的Newco交易潜力的核心要点，如今已达成的合作中，Foresite Labs、Hercules背后的贝恩资本等都是拥有运作经验的机构，可能会带来更大的胜率。 03 思考多元化的合作方式一成不变不是办法。为了活下来，Biotech能有多拼？如和铂医药、东曜药业，各自转型做CRO和ADC CDMO，如今实现盈利；开拓药业为了摆脱多次失败困境，将自家产品KX-826转向化妆品领域，以求快速面市；晶泰科技为了开源，将自身能力圈延伸到新材料领域... 在大厦将倾之时，是否可以思考多元化的合作方式？两家或三家以上的Biotech合并，可能是一个潜在的出路，在海外尤其在美国，这种案例屡见不鲜。这种方式相当于小型的并购重组，优势在于：1）几家如果管线优势协同Biotech合并后能够聚焦其中少部分核心管线，增强合并后新主体在市场的核心竞争力，同时增加了融资的可能性；2）几家公司的结合能够增厚新企业的现金储备，可延长新公司的现金跑道；3）可能给部分老股东追加注资带来更多的理由，其次提高潜在并购的可能性。这种集中优势办大事的模式，历史上并不缺乏成功案例。 2020年6月，Aduro Biotech和Chinook Therapeutics宣布进行合并且以后者为命名，组成了一个专注于肾病方向的Biotech，Aduro贡献了自主研发的APRIL单抗BION-1301，Chinook则是早在2020年初从艾伯维初获得了Atrasentan的全球权益。当时两者合并后拥有2亿美元的现金储备，同时Chinook现有投资者承诺给予2500万美元的融资，合并后将推进Atrasentan三期试验和BION-1301的一期临床。正是这次合并顺利促成了Atrasentan三期临床顺利推进且获得中期积极结果，也吸引到了关注肾病领域MNC诺华抛出橄榄枝，Chinook Therapeutics最终以35亿美元的总价被诺华溢价并购，期间公司股价涨幅高达1500%。在这个模式的层面，葆元医药与Nuvation Bio合并做出了尝试，那么接下来会不会有国内Biotech的结合呢，我们拭目以待。结语：环境可以改变人，同样可以改变一家公司。但回归到最后，还是那句“办法总比困难多”，2022年之前上市两代的Biotech能够经历过长冬的锤炼最终生存下来，那么离腾飞就更进一步了。本文转载自瞪羚社/Kris. 免责声明本文系转载，仅做分享之用，不代表平台观点。图片、文章、字体等版权均属于原作者所有，如有侵权请告知，我们会及时处理。 ------------------------------ 「长按」二维码添加小达「进群」与更多行业伙伴共探市场前沿资讯艾美达医药咨询艾美达（北京）医药信息咨询有限公司，成立于2014年4月，是一家专业的医药行业咨询服务提供商。公司致力于将产业政策研究与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业产品上市后的市场准入提供整体解决方案。

IPO财报并购

2024-03-25

·CPHI制药在线

诺华豪掷8亿美元收购IFM Due，看好STING拮抗剂在自免领域潜力

关注并星标CPHI制药在线近日，诺华收购IFM的子公司IFM Due，获得其全球首创的STING拮抗剂药物，IFM Therapeutics将收到9000万美元预付款，7.45亿美元里程碑金额，协议总金额为8.35亿美元。此次收购将使诺华获得IFM Due的STING拮抗剂组合的全部权利，该组合有潜力治疗一系列以干扰素和其他促炎细胞因子信号传导激活过度为特征的严重炎症驱动疾病。而此次价值8.35亿美元的收购这并不是诺华与IFM Due之间的第一笔交易。2019 年 9 月，诺华与IFM Due签署合作协议，共同开发抑制cGAS/STING途径的免疫疗法，治疗广泛的炎症和自身免疫疾病。根据协议条款，诺华将支付固定款项用于IFM Due的cGAS/STING项目全额研发费用，以获得收购IFM Due公司的选择权。在行使选择权时，IFM Due公司的股东将有权获得总额不超过8.4亿美元的对价。除IFM Due外，诺华与 IFM 的其他子公司达成了交易。2019 年 4 月，诺华收购了IFM 子公司 IFM Tre，支付了 3.1 亿美元的预付款和 12.6 亿美元的各种里程碑付款。通过此次收购，诺华获得了IFM Tre 旗下NLRP3抑制剂组合的全部权利。 cGAS-STING信号通路 STING是一种细胞内识别受体，通过激活cGAS-STING信号通路在调节多种基因转录中发挥重要作用。STING位于内质网(ER)的膜上，包含379个氨基酸，包括4个跨膜螺旋和一个延伸至细胞质的球形C末端结构域(CTD)。2008年，STING被发现是DNA介导的天然免疫反应中的重要成分，以应对细菌、DNA病毒等入侵。研究者证明cGAS是通过触发I型干扰素(IFN)表达来激活先天免疫的细胞溶质传感器。细胞质DNA引发cGAS-STING信号级联。这种信号传导涉及对微生物的防御，并被确定可用于癌症、自身免疫性疾病以及炎症性疾病。 cGAS-STING信号通路是细胞质DNA传感的重要过程，在调节病原体感染、肿瘤免疫和自身免疫性疾病中具有关键作用。cGAS是一种细胞质DNA转导子,通过与细胞质中的DNA结合激活干扰素调节因子 3 (IRF3)，然后以STING依赖的形式激活I型IFN的产生，导致先天性和适应性免疫的激活。在大多数肿瘤中，STING的表达受到抑制，这是肿瘤类型特异性的。当肿瘤细胞中的cGAS-STING通路被激活时，IL-6和I型IFN等细胞因子被诱导，导致肿瘤细胞凋亡或死亡。此外，释放的dsDNA和其他肿瘤衍生抗原（DAMP）可以激活树突状细胞（DC）并引发抗肿瘤免疫。此外，肿瘤来源的DNA可以被DC吸收并诱导更强的适应性抗肿瘤免疫反应。cGAS-STING信号通路通过I型干扰素等细胞因子刺激或增强先天性和适应性免疫，促进T细胞、DCs和NK细胞等免疫细胞的成熟和产生，从而触发有效的抗肿瘤作用。cGAS-STING信号通路图片来源：参考来源2 众多MNC布局STING拮抗剂免疫途径的异常激活与多种自身免疫系统疾病的发生发展息息相关，研究发现在多种自身免疫性疾病中存在cGAS-TING信号通路的失调。在自身免疫疾病的小鼠模型上，通过靶向STING 蛋白，可以抑制其下游信号通路传导，减少其介导的炎症细胞因子的产生，从而减弱小鼠自身炎症疾病的病理特征。因此，一些制药公司正在开发特异性的STING拮抗剂，希望通过抑制过度激活的STING信号通路来治疗自身免疫类疾病，如拜耳、诺华、阿斯利康等MNC通过并购或者合作引进外部创新等方式快速切入此赛道。 IFM Therapeutics是一家开发靶向先天免疫系统小分子药物的生物医药公司，STING信号通路是该公司的重要研究方向之一。公开资料显示，IFM公司开发了针对先天性免疫系统异常炎症反应的小分子拮抗剂和抑制剂，以解决包括罕见病、自身免疫性疾病、纤维化和神经退行性疾病在内的一系列适应症。目前，该公司有两个正在开发的项目：一个是口服STING小分子拮抗剂，另一个是cGAS小分子抑制剂。 IFM公司开发的候选药已获得了多家大型医药公司的青睐。除了与诺华达成得一系列合作外，百时美施贵宝也与IFM公司达成一项合作，获得了后者开发的两款先天性免疫药物的全部权益，其中一款是STING激动剂。IFM Therapeutics 产品管线图片来源：IFM Therapeutics官网 Curadev是另一家开发STING靶向疗法治疗自身免疫性疾病或炎症性疾病的公司。该公司开发的小分子STING项目旨在发现和开发STING抑制剂，以调节与各种自发炎性疾病相关的免疫反应。2020年3月，拜耳与Curadev公司达成一项研究合作和许可协议，开发新型STING拮抗剂，用于治疗肺部疾病、心血管疾病和其它炎症性疾病患者。 Aduro Biotech, Inc.是一家专注于发现、开发免疫治疗的公司，旨在改变疾病治疗的方式。公司主要利用人体的自然免疫系统来攻克疾病，目前主要研究癌症、自身免疫疾病，之后有可能扩展到传染病领域。他们研发的ADU-S100 (MIW815)是第一个进入临床的STING通路激活剂复合物。2018年12月，礼来与Aduro Biotech建立合作伙伴关系，利用Aduro的cGAS-STING通路抑制剂计划开发新的自身免疫和其他炎症性疾病的免疫疗法。礼来同意向Aduro支付1200万美元的预付款，为每一种治疗方案支付高达6.2亿美元，没有透露计划开发多少种治疗方法。 2021年7月8日，双特异性免疫疗法研发公司F-star Therapeutics（F-star）宣布已与阿斯利康（AstraZeneca）签订独占许可协议（exclusive license）。根据该协议，阿斯利康将获得研究、开发和商业化下一代干扰素基因刺激蛋白（STING）抑制剂化合物的全球权利。参考来源 1. 企业官网 2. Motwani, M., et al. (2019). DNA sensing by the cGAS-STING pathway in health and disease. Nature Reviews Genetics.doi:10.1038/s41576-019-0151-1【智药研习社近期课程预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

并购免疫疗法

2024-03-14

·PRNewswire

Pharmaceutical and Biotechnology Royalty Rates Report 2024: Essential Benchmark Data for Dealmakers - Royalty Rates, Deal Financials, Contract Documents, Royalty Rate Trends

DUBLIN, March 13, 2024 /PRNewswire/ -- The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments. This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024. The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010. Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates. Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate. In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector. Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits: Understand royalty rate trends since 2010 Analysis of the structure of royalty clauses with real life case studies Browse collaboration and licensing deals which reveal a royalty rate Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Analyzing actual contract agreements allows assessment of the following: What are the precise royalty rates granted? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction 1.1. What are royalties? 1.2. History of royalty rates 1.3. Royalties in pharmaceuticals and biotechnology 1.4. Royalties versus revenue share 1.5. Overview of the report Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates 2.1. Trends in royalty rates 2010 - 2024 2.2. How do revenue shares figure? 2.3. A review of recent literature 2.4. Royalty rates in the future Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals 3.1. Partnering agreement structure 3.2. Structure of a typical royalty clause 3.3. Example royalty clauses 3.3.1. Case study 1 3.3.2. Case study 2 3.3.3. Case study 3 3.3.4. Case study 4 Chapter 4 - Companies actively disclosing royalty rates 4.1. Most active companies in disclosing royalty rates Chapter 5 - Royalty rate contract directory Explore royalty rates within the deal contract document to gain greater insight Deal directory Deal Directory - Royalty rates in deals - by company A-Z Deal Directory - Royalty rates in deals - by therapy area Deal Directory - Royalty rates in deals - by stage of development at signing Deal Directory - Royalty rates in deals - by technology type Royalty rate references Example royalty rate deal contract document List of Figures Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024 Figure 2: Components of the partnering deal structure Figure 3: Components of the partnering royalty clause Figure 4: Most active companies disclosing royalty rate 2010 - 2024 Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies Companies Mentioned 2seventy bio 3a-diagnostics 3D Medicines 4SC 23andMe Abbott Laboratories Abbvie Abeona Therapeutics Ablynx Abraxis BioScience ABVC BioPharma ACADIA Pharmaceuticals Acceleron Pharma Acelrx Pharmaceuticals Acer Therapeutics Acerus Acrotech Biopharma Actavis (acquired by Watson) Active Biomaterials Acura Pharmaceuticals Adamis Pharmaceuticals Adaptimmune ADC Therapeutics Adeona Pharmaceuticals Adial Pharmaceuticals Aditx Therapeutics Adlai Nortye Aduro BioTech Advanced Dosage Forms Advanz Pharma Advaxis Advirna Aegerion Pharmaceutical Aeglea BioTherapeutics Aerie Pharmaceuticals AEterna Zentaris Aexon Labs Affimed Therapeutics Afritex Medical Products AFT Pharmaceuticals Agenus Bio Agios Pharmaceuticals Aguettant AiBtl BioPharma AIT Therapeutics Akcea Therapeutics Akebia Therapeutics Albert Einstein College of Medicine Alchemia Alder Biopharmaceuticals Alector Alexion Pharmaceuticals Alexza Pharmaceuticals Alfasigma Alfa Wassermann Allergan Allergan (name changed from Actavis) Almirall Alnylam Pharmaceuticals Alora Pharmaceuticals Alpha Biopharma Alternavida Altman Enterprises AltrazealTrading Altum Pharmaceuticals Alvogen Amarantus BioSciences American Type Culture Collection (ATCC) Amgen Amherst Pharmaceuticals Amorfix Life Sciences Ampio Pharmaceuticals Amryt Pharma Amylin Pharmaceuticals Amyris AnaBios AnaptysBio AnGes MG Angion Biomedica AnnaMed Antares Pharma Antibe Therapeutics Antigen Express Applied Therapeutics Apricus Biosciences Aquestive Therapeutics Aradigm Aratana Therapeutics Arcellx Arch Pharmalabs Arctic Vision Arcturus Therapeutics Arcus Biosciences Ardelyx Arena Pharmaceuticals Arrowhead Pharmaceuticals Artiva Biotherapeutics Arvinas Ascendis Pharma Ascentage Pharma Ashvattha Therapeutics Assembly Biosciences Astellas Pharma Astellas Pharma Europe Asterias Biotherapeutics AstraZeneca Athenex Atossa Therapeutics Atreca Audeo Oncology Augmenta Aurigene Discovery Technologies Aurinia Pharmaceuticals Authentic Brands Group AVEO Oncology Avita Therapeutics Avivagen Axovant Gene Therapies Axsome Therapeutics Aytu BioPharma Azaya Therapeutics Azure Biotech Baker Brothers Investments BAKX Therapeutics Baliopharm BASF Baxter International Bayer Healthcare Bayer Innovation Baylor Research Institute Beam Therapeutics BeiGene Beijing Defengrei Biotechnology Belgian Volition Bellerophon Therapeutics Benitec Biopharma Besins Healthcare Beth Israel Deaconess Medical Center BetterLife Pharma Bharat Biotech BIND Biosciences BioCorRx BioCryst Pharmaceuticals Bioeq IP Biogen BioGene Technology Biohaven Pharmaceuticals BioInvent BiolineRX BioMarin Pharmaceutical BioNovion BioNTech BioNxt Solutions Biopharmex BiopharmX BioPorto Bioprocess Capital Ventures BioProspect Biostem US Biotech Investment Biotechnology Value Fund BioTime Acquisition Bioton Biovail BioZone Laboratories BioZone Pharmaceuticals Blackstone Bluebird Bio Blueprint Medicines BMV Medica Boehringer Ingelheim Bone Therapeutics Braeburn Pharmaceuticals BrainStorm Cell Therapeutics Breathtec BioMedical Brickell Biotech BridgeBio Pharma Bridge Biotherapeutics Bristol-Myers Squibb Caleco Pharma Calico Can-Fite BioPharma Cancer Prevention Pharmaceuticals Cannassure Therapeutics CanniMed Therapeutics Cann Pharmaceutical Australia Canntab Therapeutics Cannus Partners Cantex Pharmaceuticals Cara Therapeutics Cardigant Medical Cardium Therapeutics CareFusion Carna BioSciences Cary Pharmaceuticals CASI Pharmaceuticals Castle Creek Biosciences Catalent CB2 Therapeutics Celdara Medical Celgene Cell Cure Neurosciences Cellvera Cel Sci Celyad Cereal Ingredients Cerebain Biotech Cerus CGA 369 cGreen Chi-Med Chiesi Farmaceutici Chimerix Chong Kun Dang Chongqing Jingdong Pharmaceutical Cimtech Cipher Pharmaceuticals Cipla Circassia Clal Biotech Clalit Health Services Clearmind Medicine Clearside Biomedical Clemson University Cleveland BioLabs Clinigen CMIC CNS Pharmaceuticals Cocrystal Pharma Coeptis Pharmaceuticals CohBar Cohen-McNiece Foundation Coherus Biosciences Colby Pharmaceuticals Collegium Pharmaceuticals Columbia Laboratories Columbia University Common Sense Conatus Pharmaceuticals Concile Consilient Health ContraFect Coronado Biosciences Cosmofix Cosmo Pharmaceuticals Coya Therapeutics CRISPR Therapeutics Crossject Crucell CSL CTI BioPharma CTT Pharmaceutical Cullinan Oncology Cumberland Pharmaceuticals Cures Within Reach CureTech Curis Currax Pharmaceuticals CURx Pharmaceuticals Cutanea Life Sciences Cybin CymaBay Therapeutics Cypress Bioscience Cytodyn Cytokinetics Cytori Therapeutics Daewoong Pharmaceutical Daiichi Sankyo Dana-Farber Cancer Institute Dance Biopharm DAS Therapeutics Defiante Farmaceutica Denali Therapeutics DepoMed Derma Sciences Dermavant Sciences Dermin Dianomi Therapeutics Dicerna Pharmaceuticals DNA Biomedical Solutions Dr. Falk Pharma Dr. Reddy's Laboratories Dragonfly Therapeutics DRI Capital Drugs for Neglected Diseases Initiative DS Healthcare Duke University Dyax Eagle Pharmaceuticals Eagle Pharmaceuticals (US) Easton Pharmaceuticals Echo Therapeutics Ecology Coatings Eczacibasi Pharmaceuticals Eddingpharm Egalet Eisai Elencee Eli Lilly Elite Pharmaceuticals Emergent BioSolutions Emory University Enalare Therapeutics Endocyte Endo Pharmaceuticals EnGeneIC Enochian Biosciences Entera Bio Entest BioMedical EnWave Epizyme Epocal Esperion Therapeutics Eternity Healthcare Eton Pharmaceuticals Eureka Genomics EUSA Pharma Evolva Ewopharma Exact Sciences Exelixis ExScientia Eyevance Fairview Health System FasTrack Pharmaceuticals Ferozsons Laboratories Ferring Pharmaceuticals Fibrocell Science Foghorn Therapeutics Forest Laboratories Fosun Pharmaceutical Fox Chase Chemical Diversity Center Fresenius Kabi Pharmaceuticals FSD Pharma Fusion Pharmaceuticals FusionVax Galapagos Galmed Pharmaceuticals GE Healthcare Genentech Generex Biotechnology Genevant Sciences Genexine Genfit Genmab Gentium Genzyme Geron Gilead Sciences Glaukos Glenmark Generics Inc USA Glenmark Pharmaceuticals Goldfinch Bio Government of Israel GPCR Therapeutics Gravocore Grifols GSK GT Biopharma Hai Kang Life Hail First Pharma Hainan Sihuan Pharmaceutical Halo Labs Halozyme Therapeutics Hansen Medical Health Canada Healthcare Royalty Partners Health Discovery Heartseed Heat Biologics Hefei Life Science Hefei Tianhui Incubation of Technologies HekaBio Helsinn Therapeutics HemoCleanse Hemogenyx HemPup Henlius Biotech Hetero Labs HIBM Research Group Hikma Pharmaceuticals Hoffmann La Roche Hollister Biosciences Hookipa Pharma Horizon Pharma Inc Huadong Medicine HyperGenomics I-mab Icahn School of Medicine at Mount Sinai Ice + Jam Iconovo IDC-GP Pharm IDEAYA Biosciences Idera Pharmaceuticals Idorsia Idun Pharmaceuticals IGM Biosciences iMetabolic Biopharma Immugenyx Immunic ImmunityBio Immunomedics Immunomic Therapeutics Immunovative Therapies ImmVira Impax Laboratories Imprimis Pharmaceuticals In4Derm iNAP Incannex Healthcare Incuron Incyte Indiana University Infinity Pharmaceuticals InflaRx Inhibitor Therapeutics Innate Pharma Innocoll Innovate Biopharmaceuticals Innovation Pharmaceuticals Innovent Biologics Innovet Innovus Pharmaceuticals INO Therapeutics Inspiration Biopharmaceuticals Instrumentation Laboratory IntelGenx Intellia Therapeutics IntelliCell BioSciences Intellikine Internet Marketing Consortium Intrexon Intuitive Surgical Invekra Inverness Medical Innovations Ionis Pharmaceuticals Ipsen Iroko Pharmaceuticals Ironwood Pharmaceuticals Israeli National Authority for Technological Innovation Itrom Pharmaceutical Group Ivantis Jaguar Health Janssen Biotech Janssen Pharmaceuticals Jazz Pharmaceuticals JFC Technologies Jiangsu Alphamab Jiangsu Lianhuan Pharmaceuticals Jiangsu NHWA Pharmaceutical Ji Xing Pharmaceuticals John Morley Foods Joincare Pharmaceutical Journey Medical Jubilant Life Sciences Jumpcan Pharmaceutical Juniper Pharmaceuticals Junshi Biosciences Jupiter Wellness Juventas Therapeutics K2M Kadmon Pharmaceuticals Kaken Pharmaceutical Kalbe Genexine Biologics KaloBios Pharmaceuticals Karveer Meditech KemPharm Kensey Nash Kieran Murphy Kinetic Concepts Kiniksa Pharmaceuticals Kintor Kiromic Biopharma Kite Pharma Kitov Pharma Klaria Klinge Biopharma Knighton Foods Knight Therapeutics Kodiak Sciences Kowa Kraig Biocraft Laboratories KVK-Tech Kwang Dong Pharmaceutical Kymera Therapeutics Kyowa Hakko Kirin Kyverna Therapeutics L1 Systems Laboratories Acbel Lantheus Holding Launch Therapeutics Lee Moffitt Cancer Center Legend Biotech LegoChem Biosciences Level Brands LFB Biotechnologies Lifestyle Delivery Systems Ligand Pharmaceuticals Lineage Cell Therapeutics Link Health Lipidor Lipocine Lixte Biotechnology Lorna Linda University Lotus Pharmaceuticals Loxo Oncology Lubrizol Lumenis Lundbeck Lung Therapeutics MabCure Macrogenics Magenta Therapeutics MainPointe Mallinckrodt Pharmaceuticals Marvanal Marv Enterprises Massachusetts General Hospital Matrix Biomed Mayne Pharma McComb Foundation McEwen Centre for Regenerative Medicine Meda Medica Medica Avante Medical Technologies Innovation Asia Medice Arzneimittel Putter Medicines Patent Pool Foundation Medicox MediGene Medigus MedImmune Medison Pharma Medivation Medivir Medovex MEI Pharma Melmed Memory Dx Mercer University Merck and Co Merck KGaA Merck Serono Merus Methodist Hospital Houston Micromet Mikah Pharma Millennium Mimi's Rock Mindset Pharma Ministry of Health Labor and Welfare MiNK Therapeutics Miraculins Miralogx Mira Pharmaceuticals Miromatrix Medical Mitsubishi Tanabe Pharma Moderna Modis Therapeutics Moleculin Biotech Mologen Momenta Pharmaceuticals Monash University Monopar Therapeutics Morgan Stanley MorphoSys Mount Sinai Health System MultiCell Immunotherapeutics Munich Leukemia Laboratory Mylan Laboratories Mylan Pharmaceuticals Myovant Sciences NanoVibronix NanoViricides NantCell NantKwest Nantong Jinghua Pharmaceutical NantWorks Napo Pharmaceuticals Natac Biotech Natco Pharmaceuticals National Green Biomed Nektar Therapeutics Neogenomics Neotope Nephrogenex Nephros Nestle Health Science Neuraxpharm Neurocrine Biosciences NeuroRx NeuroSigma NeuroVive Pharmaceutical NeuroVive Pharmaceutical Asia NewLeaf Brands Newsoara Biopharma New York University NexMed NextCure Nextleaf Solutions Nexvet NGM Biopharmaceuticals Nicox Nkarta Therapeutics NLS Pharmaceutics Nordic Bioscience Norgine NorthStar Medical Radioisotopes Notable Labs Novadaq Technologies NovaDel Pharma Novan Novan Therapeutics Novartis Novartis Vaccines and Diagnostics Novocure Novo Nordisk Novus Biologicals NRx Pharmaceuticals Nucorion Numab Nunzi Pharmaceutical Nurix Therapeutics Nutech Medical NutraOrigin NXTGEN Nymox Pharmaceutical Oberland Capital Ocugen Oculus Innovative Sciences Ocumension Therapeutics Omeros Oncologie Oncolytics Biotech OncoMed Pharmaceuticals Onconova Therapeutics Onegevity One Way Liver Genomics (OWL) ONK Therapeutics Ono Pharmaceutical Onxeo Onyx Pharmaceuticals Opexa Therapeutics Opthea OptiBiotix OptiNose Oragenics Oramed Pharmaceuticals Orexigen Therapeutics Organovo Orgenesis Orion Orox Pharmaceuticals OrthoCyte Otsuka OvaMed Ovid Therapeutics Oxford BioMedica Oxis Biotech Oxygen Biotherapeutics OxySure Systems Oyster Point Pharma Pan-Provincial Vaccine Enterprise Parnell Pharmaceuticals Par Pharmaceutical PDL BioPharma PDS Biotechnology Penwest Pharmaceuticals Pernix Therapeutics Perugia University Pfenex Pfizer Pharmacyclics PharmaCyte Biotech PharmaMar PharmaNova Pharmastrip Philogen Phosphagenics Photocure ASA Phusion Laboratoies Phyto Nutricare Pipex Pharmaceuticals Plandai Biotechnology Pluristem Therapeutics POINT Biopharma Portola Pharmaceuticals Poseida Therapeutics Pozen PreMD Premier Biomedical Professional Compounding Centers of America Progenics Pharmaceuticals Prometic Life Sciences ProQR Therapeutics Prosidion Protagonist Therapeutics Protalix BioTherapeutics Proteonomix Prothena ProtoKinetix Pulmatrix Puma Biotechnology QED Therapeutics QRxPharma Quick Med Technologies Quigley Corporation Quoin Pharmaceuticals Rayner Surgical Reata Pharmaceuticals Recordati Recro Pharma RedHill Biopharma Reedy Creek Investments RegenaStem Regeneron Pharmaceuticals Regenxbio Regnum Relay Therapeutics Relief Therapeutics Relmada Therapeutics RenalytixAI ReNeuron Repare Therapeutics Replicel Life Sciences Repligen Reprise Biomedical Resarci Therapeutics Retrophin rEVO Biologics Revolution Medicines Rigel Pharmaceuticals RNL Bio Roche Rockefeller University Roivant Sciences Royalty Pharma RST Biomedikal Sanayi Ruthigen RXi Pharmaceuticals S2 Therapeutics SACCO Sagard Healthcare Royalty Partners Sage Therapeutics Salix Pharmaceuticals Sam Amer Sanara MedTech Sandoz Sanofi Sanofi-Aventis Sanofi-Pasteur Sanpellegrino Cosmetics Santarus Santen Pharmaceutical Sanuwave Health SA Pathology Sapientia Pharmaceuticals Sarepta Therapeutics Schrodinger Scopus BioPharma Seagen Seattle Genetics Seelos Therapeutics Sekris Biomedical Senetek Senior Paradise Sensory Cloud Seqirus Seres Therapeutics Sermonix Pharmaceutical Sesen Bio SevenScore Pharmaceuticals Shanghai Pharmaceuticals Holdings Sheba Medical Center Shenzhen BioScien Pharmaceuticals Shield Therapeutics Shionogi Shire Pharmaceuticals Shore Therapeutics Siemens Healthcare Diagnostics Sigma-Tau Sinclair Pharmaceuticals Sinobiopharma Sinopharm Sio Gene Therapies Skinvera Skyline Diagnostics Solarvest BioEnergy Soliance Soligenix Sonoma BioTherapeutics Sorrento Therapeutics Spectranetics Spencer Pharmaceutical Spinal USA St. Jude Children's Research Hospital STADA Arzneimittel Staidson (Beijing) BioPharmaceuticals Stanford University Stealth BioTherapeutics Stellar Biotechnologies St Jude Medical Stoke Therapeutics Strongbridge Biopharma Sucampo AG SUDA Pharmaceuticals Sumitomo Dainippon Pharma Sunesis Pharmaceuticals Sunovion Pharmaceuticals Sun Pharmaceutical SuperNova Diagnostics Sutro Biopharma Swedish Orphan Biovitrum SymBio Pharmaceuticals Symbollon Syndax Pharmaceuticals Synergy Strips Syntopix Tactical Relief Taiba TaiGen Biotechnology Taiho Takeda Pharmaceutical Talaris Therapeutics Tango Therapeutics Target Group Tauriga Sciences TB Alliance TearLab Technion Research and Development Foundation Teijin Telomir Pharmaceuticals Tesaro Tetra Bio-Pharma TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Texas A&M University Texas Heart Institute TFF Pharmaceuticals TG Therapeutics Therakine TherapeuticsMD Theravance Theravance Biopharma The Regents of the University of California Thorne Research Threshold Pharmaceuticals TiGenix Tilray Titterington Veterinary Services Tiziana Life Sciences Tocagen TONIX Pharmaceuticals Torii Pharmaceutical TRACON Pharmaceuticals Tramorgan Transgene Travere Therapeutics Trellis Bioscience Trevena Trimedyne Trimeris TrovaGene TTFactor Tufts University Turnstone Biologics Tyme Technologies Ultragenyx Pharmaceuticals Uluru Unigene Laboratories UniQure Universal Cells University College Dublin University Health Network University of Alberta University of California University of Central Florida Research Foundation University of Colorado University of Florida Research Foundation University of Geneva University of Louisville University of Missouri University of Notre of Dame University of Pennsylvania University of Texas University of Virginia University of Western Sydney University of Zurich UOP Uppsalagruppen Medical Upstream Peripheral Technologies UroGen Pharma Valeant Pharmaceuticals ValiPharma Valneva Valor Biotherapeutics Vanderbilt University Vasomune Therapeutics Vaxent VBL Therapeutics Veloxis Pharmaceuticals Veracyte Verenium Verity Pharmaceuticals VeroScience Vertex Pharmaceuticals Vida Concepts Vifor Pharma ViiV Healthcare Virbac Viropharma VistaGen Therapeutics Vividion Therapeutics Vivus VolitionRX Voronoi Voyager Therapeutics Vyera Pharmaceuticals VYNE Therapeutics Vyrix Pharmaceuticals Watson Pharmaceuticals WAVE Life Sciences Wigen Biomedicine Wisconsin Alumni Research Foundation World Class Extractions WPD Pharmaceuticals WUGEN Xbrane Bioscience Xencor Xlife Sciences XPhyto Therapeutics XTL Biopharmaceuticals Xynomic Pharmaceuticals Yale University Yeda Research and Development Company Yeugnam University Yissum Research Development ZAI Laboratory Zalicus Zenitech Zenith Epigenetics Ziopharm Oncology Zogenix ZS Pharma Zymeworks For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

疫苗并购

100 项与 Aduro BioTech, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Aduro BioTech, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月24日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

环磷酰胺 ( DNA )	转移性胰腺腺癌更多	临床2期
Enistimagene Setitucel/Damistimagene Matitucel	转移性胰腺腺癌更多	临床2期
Pemlimogene merolisbac ( EGFRvIII x MSLN )	非小细胞肺癌更多	临床2期
GVAX myeloma vaccine(Cell Genesys)	多发性骨髓瘤更多	临床2期
Anti-CD27 monoclonal antibody(Aduro BioTech, Inc.) ( CD27 )	肿瘤更多	临床1期